Skip to main content

For informational and research purposes only.

Medical DisclaimerTerms of Use

5-HTP: The Definitive Guide

5-hydroxytryptophan is made from tryptophan and converted toward serotonin and melatonin. It is not dietary tryptophan, serotonin or an established antidepressant, and pathway proximity does not show that a capsule treats depression, insomnia or appetite problems.

Dietary requirement, studied exposure and clinical outcome answer different questions.
Published by DoserlyUpdated Next scheduled review: January 20277 min readHow this guide was made
In this guide

What is 5-HTP?

5-hydroxytryptophan is made from tryptophan and converted toward serotonin and melatonin. It is not dietary tryptophan, serotonin or an established antidepressant, and pathway proximity does not show that a capsule treats depression, insomnia or appetite problems. The WHO indispensable-amino-acid table assigns no adult dietary requirement to this compound; it therefore supplies no supplement target. [1]

Typical 5-HTP Research Protocols

Research schedules only; these are not prescriptions.
Source and populationForm and amount per administrationFrequencyTotal exposureDuration or window
Meloni 2020 · 25 people with Parkinson disease5-HTP 50 mgDaily; administration timing/count not reported in the abstract50 mg/day4 weeks per crossover treatment period
Meloni 2022 · 18 people with Parkinson disease and REM sleep behavior disorder5-HTP 50 mgDaily; administration timing/count not recovered50 mg/day4 weeks per crossover treatment period
Sutanto 2024 · 30 Singaporean older adults completed5-HTP 100 mg/dayDaily total; administration count and timing not recovered from accessible text100 mg/day12 weeks

These rows reproduce studies. Do not average their populations, forms, frequencies or durations into one regimen.

Dietary requirement, studied exposure and clinical claim remain separate. Sources: WHO report · Primary human study.

Should 5-HTP be cycled?

No verified trial establishes a cycle. A review point can limit indefinite use, but it does not prove a physiological reset.

What happens when it is stopped?

No withdrawal syndrome is established. An acute or short study cannot predict persistence after stopping.

Which foods provide it?

Foods provide tryptophan within protein; they do not provide a clinically comparable concentrated 5-HTP exposure. Griffonia seed extract may be standardized to 5-HTP, so record the declared 5-HTP amount rather than the extract mass alone. [1]

Which forms and label details matter?

Distinguish synthetic 5-HTP from Griffonia simplicifolia extract and record the declared 5-HTP yield. Do not transfer evidence from L-tryptophan, carbidopa-combined research, or multi-ingredient sleep products to standalone 5-HTP.

How should it be stored?

Follow the finished-product label, close the container and protect it from moisture and heat. Keep the lot number and discard a product with a broken seal or unexplained change.

What is 5-HTP commonly used for?

5-HTP is marketed for mood, sleep and appetite. Depression reviews combine small, older and heterogeneous studies; a modern Parkinson trial is preliminary and disease-specific. Sleep evidence is not a general insomnia evidence base.

What does human research show?

Javelle's 2020 review included 13 investigations and seven in meta-analysis. It estimated a large symptom effect and 65% remission proportion, but heterogeneity was high (I² 76%), doses and diagnoses varied, and few studies used placebo; the authors rated the evidence methodologically weak. The older Cochrane review found only two qualifying placebo-controlled trials with 64 total patients across 5-HTP and tryptophan and judged the evidence inconclusive. [2] Meloni enrolled 25 people with Parkinson disease in a double-blind crossover trial of 50 mg/day for four weeks per treatment. One clinician-rated depression scale improved, while apathy did not; the small, single-center, disease-specific result does not establish treatment of ordinary major depression. [3] A separate 18-person Parkinson/RBD crossover trial used 50 mg/day for four weeks. Most polysomnographic sleep outcomes and RBD manifestations did not significantly improve versus placebo, with a substantial placebo response. [4] Sutanto's single-blind 12-week trial randomized 30 Singaporean older adults who completed the study to 100 mg/day or no supplement. Selected subjective sleep components and poor-sleeper subgroup findings favored 5-HTP, while the study had no placebo, was very small, measured many sleep and microbiome outcomes, and reported exploratory subgroup results. The accessible publisher abstract contains an internally odd unit for a global-sleep-score change, so this guide does not repeat that numerical effect. It does not establish a general insomnia dose. [5]

Conceptual hierarchy connecting mechanism, human study and clinical outcome.
An acute study, biomarker, tolerance study and clinical outcome answer different questions.

How might it act?

Aromatic L-amino-acid decarboxylase converts 5-HTP to serotonin in peripheral and central pathways. That mechanism also explains interaction risk: raising precursor availability is not the same as selectively correcting a diagnosed brain serotonin deficit.

What are the risks and interactions?

Nausea, vomiting, diarrhea, abdominal discomfort, headache and sleepiness can occur. Because 5-HTP feeds serotonin synthesis, avoid unsupervised combinations with SSRIs, SNRIs, MAO inhibitors, tricyclic antidepressants, linezolid, tramadol, dextromethorphan, St John's wort or other serotonergic products. Agitation, tremor, sweating, diarrhea, fever or confusion after a combination needs urgent assessment. Product purity matters; pregnancy, breastfeeding, childhood use and major psychiatric or neurologic disease require clinician review.

Which medicines can interact?

Product-specific interaction data are limited. Have the complete formula reviewed by a pharmacist when taking medicines, especially for neurologic, psychiatric, metabolic, kidney or liver conditions. Do not invent a universal separation interval.

Regulatory status: In the United States, supplements are not routinely approved for efficacy before sale. In Canada, check the NPN or DIN-HM and licensed label conditions. [7], [8]

What should be monitored?

Record product, lot, form, amount per administration, frequency, daily total, co-ingredients, dietary context, symptoms and intended outcome. Set a review date before starting.

Stop and seek advice for an allergic reaction, persistent vomiting, unusual weakness, confusion or another severe symptom.

What do public communities report?

Public discussions often emphasize taste, timing and felt effects while omitting lot, total diet and validated outcomes. This update did not independently recrawl or quantify those posts.

How does 5-HTP compare?

OptionWhat it suppliesLimit
5-HTPOne defined amino acidDoes not replace complete protein
EAAsAll nine indispensable amino acidsFormula varies
BCAAsLeucine, isoleucine and valineSix EAAs are absent
Complete proteinAll EAAs in a protein matrixPortion and digestibility vary

Common questions about 5-HTP

Does 5-HTP treat depression?

Evidence is too weak and heterogeneous to treat it as an established antidepressant; diagnosed depression needs evidence-based care.

Does it reliably improve sleep?

No general insomnia regimen is established. A small Parkinson/RBD trial found mostly nonsignificant objective effects.

Is Griffonia extract the same as 5-HTP?

Only the standardized 5-HTP yield can be compared. Extract mass alone is not the active 5-HTP amount.

Can it be combined with an antidepressant?

Do not combine it without prescriber or pharmacist review because serotonergic effects can add.

Is 50 mg/day a recommended dose?

No. It was a disease-specific research exposure, not a general recommendation.

What should I track?

Record declared 5-HTP per administration, extract yield, timing, medicines, mood or sleep measure, GI effects and review date.

Glossary

Plain terms for interpreting the evidence.

Indispensable amino acid
An amino acid the diet must provide.
Dietary requirement
Total required intake; not a supplement dose.
Amount per administration
Amount consumed at one time, distinct from daily total.
NOAEL
Highest tested level without an observed adverse effect in one study; not automatically a UL.
UL
Tolerable Upper Intake Level established by an authority.
Biomarker
Biological measure that is not necessarily a felt or clinical benefit.

How this guide was researched

The complete WHO report, accessible primary human studies and live NCBI metadata were read on October 9, 2026. Titles, authors, journals, DOI, PMID, available PMCID and CommentsCorrections were checked. Open full text supplied methods details; an unreported frequency was not guessed. [1], [2], [3], [4], [5], [6], [7], [8]

How this guide was made

Research and drafting were AI-assisted. This draft awaits Doserly editorial review and independent clinical review. See the editorial policy.

Explore the sources

Sources preserve form, dose, frequency, population, duration and outcome.

Showing 8 sources

  1. 01

    Protein and amino acid requirements in human nutrition: report of a joint WHO/FAO/UNU expert consultation ↗

    Official expert report

    Current primary source and identity checked; limitations are retained in the text.

    Detail: 5-hydroxytryptophan is not assigned an adult dietary requirement in WHO Table 49; it is a serotonin-pathway intermediate, not dietary tryptophan.

  2. 02

    Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis. ↗

    Systematic review and meta-analysis

    Current primary source and identity checked; limitations are retained in the text.

    Detail: 13 investigations; seven meta-analyzed; high heterogeneity and generally weak methods with few placebo groups.

  3. 03

    Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding. ↗

    Small randomized crossover trial

    Current primary source and identity checked; limitations are retained in the text.

    Detail: 25 people with Parkinson disease; 50 mg/day for four weeks per treatment; clinician-rated depression signal, apathy null.

  4. 04

    Tryptophan and 5-hydroxytryptophan for depression. ↗

    Updated Cochrane systematic review

    Current primary source and identity checked; limitations are retained in the text.

    Detail: The 2002 update (PMID 11869656) supersedes the 2001 PubMed record; only two qualifying trials with 64 total patients across 5-HTP and tryptophan, so evidence remained insufficient.

  5. 05

    Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease. ↗

    Small Parkinson sleep crossover trial

    Current primary source and identity checked; limitations are retained in the text.

    Detail: 18 people; 50 mg/day for four weeks; most objective sleep and RBD outcomes were not significantly different from placebo.

  6. 06

    The impact of 5-hydroxytryptophan supplementation on sleep quality and gut microbiota composition in older adults: A randomized controlled trial ↗

    Small single-blind older-adult trial

    Current primary source and identity checked; limitations are retained in the text.

    Detail: 30 completers; 100 mg/day for 12 weeks versus no supplement; selected subjective and poor-sleeper subgroup signals, no placebo.

  7. 07

    Questions and Answers on Dietary Supplements ↗

    U.S. regulatory overview

    Current primary source and identity checked; limitations are retained in the text.

    Detail: Dietary supplements are not routinely FDA-approved for efficacy before sale.

  8. 08

    Product Licensing ↗

    Canadian licensing overview

    Current primary source and identity checked; limitations are retained in the text.

    Detail: Canadian authorization attaches to the licensed finished product and label conditions.